

## **Appendix 16a: Evidence profile tables A16-1 to A16-6 (brief interventions)**

<b>Brief interventions .....</b>	<b>2</b>
Table A16-1. Stand alone brief interventions .....	2
Table A16-2. Adjunctive brief interventions .....	4
Table A16-3. Contingency management for harm reduction .....	6
Table A16-4. HIV psychoeducation versus HIV standard education .....	8
Table A16-5. HIV psychoeducation versus standard education (for at risk population).....	10
Table A16-6. HIV psychoeducation versus self help leaflet .....	12

## Brief interventions

**Table A16-1. Stand alone brief interventions**

### Quality assessment

No of studies	Design	Limitations	Consistency	Directness	Other considerations
<b>Abstinence from stimulants (6 month follow up) (Baker2005, Bernstein2005, Marsden2006)</b>					
3	Randomised trials	No limitations	No important inconsistency	No uncertainty	None
<b>Abstinence from heroin (6 month follow up) (Bernstein 2005)</b>					
1	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	Imprecise or sparse data (-1) <sup>2</sup>
<b>Abstinence from poly-drug use (heroin and cocaine): 6 month follow up (Bernstein2005)</b>					
1	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	Imprecise or sparse data (-1) <sup>2</sup>
<b>Abstinence from cannabis (4 month follow up) (Stephens 2000, 2002)</b>					
2	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	Strong association (+1) <sup>3</sup>

### Summary of findings

Outcome	No of patients		Effect		Quality
	Brief Interventions	Control	Relative (95% CI)	Absolute (95% CI)	

Abstinence from stimulants (6 month follow up)	201/643 (31.3%)	154/625 (24.6%)	RR 1.30 (1.09 to 1.55)	-	High
Abstinence from heroin (6 month follow up)	151/403 (37.5%)	115/375 (30.7%)	RR 1.22 (1.00 to 1.49)	-	Low
Abstinence from cannabis (4 month follow up)	39/203 (19.2%)	12/216 (5.6%)	RR 3.44 (1.87 to 6.33)	-	High

**Footnotes:**

1. No UK study
2. 1 study
3. RR >2

**Table A16-2. Adjunctive brief interventions**

**Quality assessment**

No of studies	Design	Limitations	Consistency	Directness	Other considerations
<b>Days of drug use (28 day follow up) Carroll (2006a)</b>					
1	Randomised trials	No limitations	No important inconsistency	No uncertainty	Imprecise or sparse data (-1) <sup>1,2</sup>
<b>Post-detox cocaine use Stotts (2001)</b>					
1	Randomised trials	No limitations	No important inconsistency	No uncertainty	Imprecise or sparse data (-1) <sup>1</sup>
<b>Completion of treatment Stotts (2001)</b>					
1	Randomised trials	No limitations	No important inconsistency	No uncertainty	Imprecise or sparse data (-1) <sup>1,2</sup>

**Summary of findings**

Outcome	No of patients		Effect		Quality
	Brief interventions	Control	Relative (95% CI)	Absolute (95% CI)	
Days of drug use (28 day follow up)	165	171	-	SMD -0.11 (-0.36 to 0.13)	⊕⊕⊕○ Moderate
Post-detox cocaine use	23/26 (88.5%)	16/26 (61.5%)	RR 1.44 (1.03 to 2.01)	-	⊕⊕⊕○ Moderate
Abstinence from drugs and heavy	127/295 (43.1%)	128/284 (45.1%)	RR 0.96 (0.79 to 1.15)	-	⊕⊕⊕○ Moderate

drinking						
Engaged in further treatment	465/527 (88.2%)	440/529 (83.2%)	RR 1.06 (1.01 to 1.11)	-	 Moderate	
Completion of treatment	26/52 (50%)	26/53 (49.1%)	RR 1.02 (0.69 to 1.50)	-	 Moderate	

**Footnotes:**

1. 1 study
2. CIs compatible with benefit and no benefit
3. I-squared~50%

**Table A16-3. Contingency management for harm reduction**

**Quality assessment**

No of studies	Design	Limitations	Consistency	Directness	Other considerations
<b>Returned for TB test or Hep B vaccination (One-off CM) (Malotte 1998, Malotte 1999, Seal 2003)</b>					
3	Randomised trials	No limitations	Important inconsistency (-1) <sup>2</sup>	Some uncertainty (-1) <sup>1</sup>	Strong association (+1) <sup>3</sup>
<b>Completion of full course of medication/prophylaxis (Long term CM) ((Malotte 2001, Seal 2003)</b>					
2	Randomised trials	No limitations	Important inconsistency (-1) <sup>2</sup>	Some uncertainty (-1) <sup>1</sup>	Very strong association (+2) <sup>4</sup>
<b>Proportion of HIV medication taken on time - during treatment (Longer term CM) ((Rosen 2007, Sorensen 2006)</b>					
2	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	Strong association (+1) <sup>6</sup>
<b>Proportion of HIV medication taken on time - 1 month follow up (Longer term CM) ((Rosen 2007, Sorensen 2006)</b>					
2	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	None

**Summary of findings**

Outcome	No of patients		Effect		Quality
	CM	Control	Relative (95% CI)	Absolute (95% CI)	
Returned for TB test or Hep B vaccination (One-off CM)	438/468 (93.6%)	169/363 (46.6%)	RR 2.00 (1.48 to 2.72)	-	⊕⊕⊕○ Moderate

Completion of full course of medication/prophylaxis (Long term CM)	66/103 (64.1%)	13/103 (12.6%)	RR 6.38 (1.00 to 40.54)	-	High
Proportion of HIV medication taken on time - during treatment (Longer term CM)	62	60	-	SMD -1.16 (-1.55 to -0.78)	High
Proportion of HIV medication taken on time - 1 month follow up (Longer term CM)	62	60	-	SMD -0.49 (-0.85 to -0.13)	Moderate

**Footnotes:**

1. No UK studies
2. I-squared > 50%
3. RR =2
4. RR > 5
5. SMD > 0.8

**Table A16-4. HIV psychoeducation versus HIV standard education**

**Quality assessment**

No of studies	Design	Limitations	Consistency	Directness	Other considerations
<b>Injection risk behaviour</b> Kotranski (1998), Siegal (1995), Epstein (2003)					
3	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	Imprecise or sparse data (-1) <sup>3</sup>
<b>Sexual risk behaviour</b> Eldridge (1997), Kotranski (1998), Malow (1994), Epstein (2003), Weschberg (2004)					
6	Randomised trials	No limitations	Important inconsistency (-1) <sup>2</sup>	Some uncertainty (-1) <sup>1</sup>	None
<b>Reduction in injection risk behaviour</b> Avants (2004), Baker (1993), O'Neill (1996)					
3	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	None
<b>reduction in sexual risk behaviour</b> Avants (2004), Baker (1993), Eldridge (1997), Harris (1998), O'Neill (1996)					
5	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	None

**Summary of findings**

Outcome	No of patients		Effect		Quality
	HIV Psychoeducation	HIV Standard Education	Relative (95% CI)	Absolute (95% CI)	
Injection risk behaviour	81/401 (20.2%)	105/440 (23.9%)	RR 0.95 (0.73 to 1.23)	-	⊕⊕○○ Low

Sexual risk behaviour	312/592 (52.7%)	292/531 (55%)	RR 0.91 (0.73 to 1.12)	-	 Low
Reduction in injection risk behaviour	176	177	-	SMD -0.21 (-0.42 to 0.00)	 Moderate
reduction in sexual risk behaviour	278	263	-	SMD -0.30 (-0.47 to -0.13)	 Moderate

**Footnotes:**

1. No UK studies
2. I-squared ~50%
3. CIs compatible with benefit and no benefit

**Table A16-5. HIV psychoeducation versus standard education (for at risk population)**

**Quality assessment**

No of studies	Design	Limitations	Consistency	Directness	Other considerations
<b>Safer Injecting risk behaviour (end of treatment)</b> Colon (1993), Kotranski (1998), Siegal (1995)					
3	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	Imprecise or sparse data (-1) <sup>3</sup>
<b>Safer sexual behaviour (end of treatment)</b> Colon (1993), Kotranski (1998), Malow (1994)					
3	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	None

**Summary of findings**

Outcome	No of patients		Effect		Quality
	HIV psychoeducation	Standard education	Relative (95% CI)	Absolute (95% CI)	
Safer Injecting risk behaviour (end of treatment)	333/598 (55.7%)	342/663 (51.6%)	RR 1.09 (0.98 to 1.21)	-	⊕⊕○○ Low

Safer sexual behaviour (end of treatment)	143/570 (25.1%)	97/625 (15.5%)	RR 1.56 (1.25 to 1.95)	-	 Moderate
--	--------------------	-------------------	---------------------------	---	---

**Footnotes:**

1. No UK studies
2. CIs compatible with benefit and no benefit

**Table A16-6. HIV psychoeducation versus self help leaflet**

**Quality assessment**

No of studies	Design	Limitations	Consistency	Directness	Other considerations
<b>reduction in injection risk behaviour</b> Baker (1993), Sorensen (1994: MMT), Sorensen (1994: Detox)					
3	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	Imprecise or sparse data (-1) <sup>3</sup>
<b>reduction in sexual risk behaviour (post-treatment)</b> (Baker (1993), Schilling (1991), Sorensen (1994: MMT), Sorensen (1994: Detox))					
4	Randomised trials	No limitations	No important inconsistency	Some uncertainty (-1) <sup>1</sup>	None

**Summary of findings**

Outcome	No of patients		Effect		Quality
	HIV psychoeducation	self help leaflet	Relative (95% CI)	Absolute (95% CI)	
reduction in injection risk behaviour	85	81	-	SMD -0.02 (-0.33 to 0.29)	⊕⊕○○ Low
reduction in sexual risk behaviour (post-treatment)	131	119	-	SMD -0.32 (-0.57 to -0.07)	⊕⊕⊕○ Moderate

**Footnotes:**

1. No UK studies
2. I-squared ~ 50%
3. CIs compatible with benefit and no benefit